Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 102


MEK1/2 inhibition promotes Taxotere lethality in mammary tumors in vivo.

Yacoub A, Gilfor D, Hawkins W, Park MA, Hanna D, Hagan MP, Curiel DT, Fisher PB, Grant S, Dent P.

Cancer Biol Ther. 2006 Oct;5(10):1332-9. Epub 2006 Oct 15.


Transient exposure of mammary tumors to PD184352 and UCN-01 causes tumor cell death in vivo and prolonged suppression of tumor regrowth.

Hawkins W, Mitchell C, McKinstry R, Gilfor D, Starkey J, Dai Y, Dawson K, Ramakrishnan V, Roberts JD, Yacoub A, Grant S, Dent P.

Cancer Biol Ther. 2005 Nov;4(11):1275-84. Epub 2005 Dec 1.


Sequence dependent exposure of mammary carcinoma cells to Taxotere and the MEK1/2 inhibitor U0126 causes enhanced cell killing in vitro.

Yacoub A, Han SI, Caron R, Gilfor D, Mooberry S, Grant S, Dent P.

Cancer Biol Ther. 2003 Nov-Dec;2(6):670-6.


Transient exposure of carcinoma cells to RAS/MEK inhibitors and UCN-01 causes cell death in vitro and in vivo.

Hamed H, Hawkins W, Mitchell C, Gilfor D, Zhang G, Pei XY, Dai Y, Hagan MP, Roberts JD, Yacoub A, Grant S, Dent P.

Mol Cancer Ther. 2008 Mar;7(3):616-29. doi: 10.1158/1535-7163.MCT-07-2376.


Pharmocologic inhibitors of the mitogen activated protein kinase cascade have the potential to interact with ionizing radiation exposure to induce cell death in carcinoma cells by multiple mechanisms.

Qiao L, Yacoub A, McKinstry R, Park JS, Caron R, Fisher PB, Hagan MP, Grant S, Dent P.

Cancer Biol Ther. 2002 Mar-Apr;1(2):168-76.


MEK1/2 inhibitors potentiate UCN-01 lethality in human multiple myeloma cells through a Bim-dependent mechanism.

Pei XY, Dai Y, Tenorio S, Lu J, Harada H, Dent P, Grant S.

Blood. 2007 Sep 15;110(6):2092-101. Epub 2007 May 31.


The role of the polyamine catabolic enzymes SSAT and SMO in the synergistic effects of standard chemotherapeutic agents with a polyamine analogue in human breast cancer cell lines.

Pledgie-Tracy A, Billam M, Hacker A, Sobolewski MD, Woster PM, Zhang Z, Casero RA, Davidson NE.

Cancer Chemother Pharmacol. 2010 May;65(6):1067-81. doi: 10.1007/s00280-009-1112-8. Epub 2009 Aug 30.


Enhancing CHK1 inhibitor lethality in glioblastoma.

Tang Y, Dai Y, Grant S, Dent P.

Cancer Biol Ther. 2012 Apr;13(6):379-88. doi: 10.4161/cbt.19240. Epub 2012 Apr 1.


Inactivation of NF-kappaB by 3,3'-diindolylmethane contributes to increased apoptosis induced by chemotherapeutic agent in breast cancer cells.

Rahman KM, Ali S, Aboukameel A, Sarkar SH, Wang Z, Philip PA, Sakr WA, Raz A.

Mol Cancer Ther. 2007 Oct;6(10):2757-65. Epub 2007 Oct 3.


Tumor inhibitory effect of gefitinib (ZD1839, Iressa) and taxane combination therapy in EGFR-overexpressing breast cancer cell lines (MCF7/ADR, MDA-MB-231).

Takabatake D, Fujita T, Shien T, Kawasaki K, Taira N, Yoshitomi S, Takahashi H, Ishibe Y, Ogasawara Y, Doihara H.

Int J Cancer. 2007 Jan 1;120(1):181-8.


Inhibitors of MEK1/2 interact with UCN-01 to induce apoptosis and reduce colony formation in mammary and prostate carcinoma cells.

McKinstry R, Qiao L, Yacoub A, Dai Y, Decker R, Holt S, Hagan MP, Grant S, Dent P.

Cancer Biol Ther. 2002 May-Jun;1(3):243-53.


TGFβ1 inhibition increases the radiosensitivity of breast cancer cells in vitro and promotes tumor control by radiation in vivo.

Bouquet F, Pal A, Pilones KA, Demaria S, Hann B, Akhurst RJ, Babb JS, Lonning SM, DeWyngaert JK, Formenti SC, Barcellos-Hoff MH.

Clin Cancer Res. 2011 Nov 1;17(21):6754-65. doi: 10.1158/1078-0432.CCR-11-0544. Epub 2011 Oct 25.


'Rings' of F-actin form around the nucleus in cultured human MCF7 adenocarcinoma cells upon exposure to both taxol and taxotere.

Rosenblum MD, Shivers RR.

Comp Biochem Physiol C Toxicol Pharmacol. 2000 Jan;125(1):121-31.


The farnesyl protein transferase inhibitor SCH66336 synergizes with taxanes in vitro and enhances their antitumor activity in vivo.

Shi B, Yaremko B, Hajian G, Terracina G, Bishop WR, Liu M, Nielsen LL.

Cancer Chemother Pharmacol. 2000;46(5):387-93.


Inhibition of growth of MDA-MB-468 estrogen-independent human breast carcinoma by bombesin/gastrin-releasing peptide antagonists RC-3095 and RC-3940-II.

Kahán Z, Sun B, Schally AV, Arencibia JM, Cai RZ, Groot K, Halmos G.

Cancer. 2000 Mar 15;88(6):1384-92.


Supplemental Content

Support Center